Analyst Price Targets — BVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 12:55 pm | — | Barrington | $13.00 | $8.51 | TheFly | Bioventus initiated with an Outperform at Barrington |
| May 7, 2025 1:16 pm | Chase Knickerbocker | Craig-Hallum | $15.00 | $6.20 | TheFly | Bioventus price target lowered to $15 from $17 at Craig-Hallum |
| October 1, 2024 1:38 pm | Caitlin Cronin | Canaccord Genuity | $12.00 | $11.79 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS) |
| August 7, 2024 9:05 am | Chase Knickerbocker | Craig-Hallum | $12.00 | $8.25 | TheFly | Bioventus price target raised to $12 from $9 at Craig-Hallum |
| May 7, 2024 1:38 pm | William Plovanic | Canaccord Genuity | $8.00 | $5.12 | StreetInsider | Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity |
| March 13, 2024 8:42 am | Alex Nowak | Craig-Hallum | $9.00 | $5.29 | StreetInsider | Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum |
| November 30, 2022 8:31 am | — | Goldman Sachs | $2.50 | $1.91 | Benzinga | Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5 |
Latest News for BVS
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the…
Bioventus (NASDAQ: BVS - Get Free Report) and Nanovibronix (NASDAQ: FEED - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership. Earnings and Valuation This table compares Bioventus and Nanovibronix"s
Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET).
Bioventus (NYSE: BVS - Get Free Report) and Medifocus (OTCMKTS:MDFZF - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability. Earnings and Valuation This table compares Bioventus and Medifocus"s
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BVS.
U.S. House Trading
No House trades found for BVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.